OBJECTIVES: Both generic and disease-specific measures can be a useful strategy for assessing HRQoL outcomes. This post-hoc analysis evaluated the ability of the generic EQ-5D-3L instrument and the OAB-5D disease-specific instrument, to assess changes in men with LUTS/BPH who have moderate-to-severe storage symptoms and voiding symptoms treated with fixed-dose combination (FDC) of solifenacin 6mg + oral controlled absorption system [OCAS™] formulation of tamsulosin (TOCAS, 0.4mg), TOCAS monotherapy, or placebo. METHODS: Data were available from a 12-week clinical trial (NEPTUNE). Patients completed the OAB-5D and EQ-5D-3L (including EQ-VAS) instruments. Analyses controlled for relevant patient characteristics. Analysis of covariance estimated and compared changes from baseline at each time point for EQ-5D-3L, EQ-VAS and OAB-5D.  RESULTS: Statistically significant differences were seen in OAB-5D utilities with TOCAS monotherapy and FDC solifenacin 6mg + TOCAS compared with placebo after 4, 8 and 12 weeks in the overall population. When patients reporting full-health on EQ-5D-3L at baseline were excluded from the analysis to reduce the ceiling effect, the improvement from baseline (Δ